Bio-Path Holdings, Inc.
BPTH- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001133818
No open-market purchases or sales by Bio-Path Holdings, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Bio-Path Holdings, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 10
- −9 vs. Q4 2023
- Shares held
- 19.1K
- −10.8K (−36.1%) vs. Q4 2023Converted for a 1-for-20 split
- Total value
- $78.6K
- −$197.9K (−71.6%) vs. Q4 2023
- New holders
- 0
- 4 more added
- Sold out
- 9
- 4 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BPTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 2 | $5.29K |
| Q4 2024 | 22 | $370.1K |
| Q3 2024 | 14 | $53.5K |
| Q2 2024 | 13 | $285.1K |
| Q1 2024 | 10 | $78.6K |
| Q4 2023 | 19 | $276.5K |
| Q3 2023 | 23 | $256.6K |
| Q2 2023 | 18 | $812.0K |
| Q1 2023 | 21 | $793.1K |
| Q4 2022 | 21 | $976.3K |
| Q3 2022 | 19 | $1.47M |
| Q2 2022 | 17 | $1.59M |
| Q1 2022 | 17 | $1.51M |
| Q4 2021 | 17 | $1.70M |
| Q3 2021 | 17 | $2.23M |
| Q2 2021 | 17 | $2.94M |
| Q1 2021 | 19 | $3.31M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Bio-Path Holdings, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 13,502 | $55.6K | 0.00% | 00.0% | UnchangedConverted for a 1-for-20 split |
| BlackRock Inc. | 2,381 | $9.81K | 0.00% | −354−13.0% | ReducedConverted for a 1-for-20 split |
| Tower Research Capital LLC (TRC) | 1,934 | $7.97K | 0.00% | +1,448+297.8% | AddedConverted for a 1-for-20 split |
| UBS Group AG | 1,177 | $4.85K | 0.00% | +38+3.3% | AddedConverted for a 1-for-20 split |
| Morgan Stanley | 35 | $144 | 0.00% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Group One Trading, L.P. | 21 | $89 | 0.00% | −254−92.4% | ReducedConverted for a 1-for-20 split |
| Bank of America Corp | 7 | $29 | 0.00% | −1−7.9% | ReducedConverted for a 1-for-20 split |
| Wells Fargo & Company | 5 | $20 | 0.00% | +0+5.3% | AddedConverted for a 1-for-20 split |
| Global Retirement Partners, LLC | 4 | $16 | 0.00% | +1+15.9% | AddedConverted for a 1-for-20 split |
| Allworth Financial LP | 1 | $5 | 0.00% | −7−86.7% | ReducedConverted for a 1-for-20 split |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −5,522−100.0% | Sold outConverted for a 1-for-20 split |
| Strategic Advocates LLC | 0 | $0 | 0.00% | −1,756−100.0% | Sold outConverted for a 1-for-20 split |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −1,210−100.0% | Sold outConverted for a 1-for-20 split |
| Northern Trust Corp | 0 | $0 | 0.00% | −886−100.0% | Sold outConverted for a 1-for-20 split |
| HRT Financial LP | 0 | $0 | 0.00% | −865−100.0% | Sold outConverted for a 1-for-20 split |
| XTX Topco Ltd | 0 | $0 | 0.00% | −770−100.0% | Sold outConverted for a 1-for-20 split |
| State Street Corp | 0 | $0 | 0.00% | −652−100.0% | Sold outConverted for a 1-for-20 split |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −1−100.0% | Sold outConverted for a 1-for-20 split |
| Royal Bank of Canada | 0 | $0 | 0.00% | −1−100.0% | Sold outConverted for a 1-for-20 split |